{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Baricitinib&page=2",
    "query": {
      "intervention": "Baricitinib",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Baricitinib&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T14:27:48.744Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01683409",
      "title": "A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2012-08",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2019-09-30",
      "last_synced_at": "2026-09-22T14:27:48.744Z",
      "location_count": 35,
      "location_summary": "Lancaster, California • San Diego, California • Torrance, California + 32 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01683409"
    },
    {
      "nct_id": "NCT04340232",
      "title": "Safety and Efficacy of Baricitinib for COVID-19",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-03",
      "completion_date": "2021-10",
      "has_results": false,
      "last_update_posted_date": "2021-03-08",
      "last_synced_at": "2026-09-22T14:27:48.744Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04340232"
    },
    {
      "nct_id": "NCT01724580",
      "title": "Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)",
        "Juvenile Dermatomyositis (JDM)",
        "Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)",
        "Aicardi-Goutières Syndrome (AGS)"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2025-01-17",
      "last_synced_at": "2026-09-22T14:27:48.744Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01724580"
    },
    {
      "nct_id": "NCT07222332",
      "title": "A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "1 Year to 35 Years"
      },
      "enrollment_count": 300,
      "start_date": "2026-02-05",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-22T14:27:48.744Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Tallahassee, Florida • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Corpus Christi",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222332"
    },
    {
      "nct_id": "NCT06631287",
      "title": "Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Long COVID",
        "Sars-CoV-2 Infection",
        "Coronavirus Infections",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wes Ely",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2024-10-21",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-09-22T14:27:48.744Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06631287"
    },
    {
      "nct_id": "NCT01721044",
      "title": "A Moderate to Severe Rheumatoid Arthritis Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "cDMARD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 527,
      "start_date": "2013-01",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2019-09-18",
      "last_synced_at": "2026-09-22T14:27:48.744Z",
      "location_count": 32,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01721044"
    },
    {
      "nct_id": "NCT06240351",
      "title": "A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Frontal Fibrosing Alopecia"
      ],
      "interventions": [
        {
          "name": "Baricitinib 4 MG Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2024-04-22",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-09-22T14:27:48.744Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06240351"
    },
    {
      "nct_id": "NCT04421027",
      "title": "A Study of Baricitinib (LY3009104) in Participants With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1525,
      "start_date": "2020-06-12",
      "completion_date": "2021-06-10",
      "has_results": true,
      "last_update_posted_date": "2022-07-28",
      "last_synced_at": "2026-09-22T14:27:48.744Z",
      "location_count": 25,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04421027"
    },
    {
      "nct_id": "NCT05723198",
      "title": "A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Areata Alopecia",
        "Alopecia",
        "Hypotrichosis",
        "Hair Diseases",
        "Skin Diseases",
        "Pathological Conditions, Anatomical"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 595,
      "start_date": "2023-02-27",
      "completion_date": "2033-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-09-22T14:27:48.744Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05723198"
    },
    {
      "nct_id": "NCT03742973",
      "title": "A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cholangitis"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2019-03-28",
      "completion_date": "2019-09-26",
      "has_results": true,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-09-22T14:27:48.744Z",
      "location_count": 10,
      "location_summary": "Coronado, California • Sacramento, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03742973"
    }
  ]
}